Long-term effects of weight-reducing drugs in people with hypertension.

TL;DR

A major Cochrane review of 8 randomized trials involving 13,000 hypertensive patients found no clear evidence that weight-loss drugs reduce death or heart attacks in people with high blood pressure. The evidence gap is so large that stronger, more targeted research is needed before drawing conclusions about real-world benefits.

What the study found

This Cochrane systematic review examined the long-term effects of FDA-approved weight-loss medications in adults with hypertension. Researchers searched medical databases through April 2024 and identified 8 randomized controlled trials comparing five different drug classes to placebo: orlistat, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide. Across these trials, approximately 13,000 hypertensive participants were followed for 6 to 48 months. This represents a substantial body of research, yet the quality and consistency of outcomes reported varied dramatically.

The critical finding: none of the drug classes demonstrated clear benefits for the outcomes that matter most in hypertension management. For orlistat, the oldest drug in the analysis, mortality data came from only 3 deaths across 1,488 participants over roughly 1-3 years, providing very low certainty evidence. Cardiovascular events were similarly sparse and inconsistent across trials. The two newest drugs, semaglutide and tirzepatide, did not report mortality, cardiovascular disease, or serious adverse event data at all in their hypertension-specific trials, leaving the critical question entirely unanswered for these agents.

When researchers examined secondary outcomes, weight loss did occur with most drugs compared to placebo, and modest blood pressure reductions were observed. However, this created a gap between mechanism (weight loss leads to lower blood pressure) and outcome (does lower blood pressure from drugs prevent death and cardiac events?). This gap is precisely why long-term mortality and cardiovascular event data matter: weight loss itself is not the clinical goal; preventing heart attacks and strokes is.

The safety picture was mixed but concerning. Orlistat probably increased serious adverse events by 45% relative to placebo (moderate certainty). Naltrexone/bupropion and phentermine/topiramate both increased overall adverse events substantially compared to placebo. For phentermine/topiramate, there was a trend toward more treatment-emergent cardiac events on the high dose, though the confidence intervals were wide and the evidence was rated very uncertain. These signals warrant attention, especially in a population already at elevated cardiovascular risk.

What this means for you

The practical message is straightforward: evidence that weight-loss drugs prevent serious outcomes in hypertensive patients remains insufficient. If you have hypertension and are considering these medications, the decision cannot be based on demonstrated mortality or cardiovascular benefit. The evidence gap exists not because these drugs are necessarily ineffective, but because the trials conducted so far were not designed to answer the question.

For clinicians and patients evaluating options, this review suggests three takeaways. First, lifestyle approaches to weight loss and blood pressure management remain the evidence-based foundation. Post-meal walks, protein at every meal, high-fiber diet, and zone-2 cardio are supported by consistent evidence for cardiovascular benefit. Second, if pharmacological weight loss is considered, individual risk-benefit discussion is essential, given modest blood pressure reductions balanced against increased adverse events. Third, the absence of mortality and cardiovascular disease data in trials of newer agents like semaglutide and tirzepatide is a notable gap, particularly given their widespread adoption.

The review also highlights a methodological problem: many completed trials enroll both normotensive and hypertensive participants but do not publish separate results for the hypertension subgroup. This makes it impossible for patients and clinicians to know whether findings from the overall population apply to people with high blood pressure. Future research should address this directly.

Study details

Sources

Cochrane Hypertension Group. "Long-term effects of weight-reducing drugs in people with hypertension." The Cochrane Database of Systematic Reviews, 2024. PubMed: 42318855